Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry

BMC Geriatrics

Research Article

Armelle Gentric¹  Virginie Jannou²  François-Mathias Merrien³  Philippe Goas³  Serge Timsit³  François Rouhart³  Anne Tirel-Badets³  Irina Viakhireva-Dovganyuk³  Emmanuel Nowak⁴ 

[1] Department of Internal Medicine and Geriatrics, University Hospital of Brest, Boulevard Tanguy Prigent, 29200, Brest, Bretagne, France;Department of Internal Medicine and Geriatrics, University Hospital of Brest, Boulevard Tanguy Prigent, 29200, Brest, Bretagne, France;Neurology and Stroke Department, University Hospital of Brest, Boulevard Tanguy Prigent, 29200, Brest, Bretagne, France;Neurology and Stroke Department, University Hospital of Brest, Boulevard Tanguy Prigent, 29200, Brest, Bretagne, France;University Hospital of Brest, CIC INSERM, Boulevard Tanguy Prigent, 29200, Brest, Bretagne, France;

关键词: Stroke;    Atrial fibrillation;    CHADS2;    Anticoagulation;    Registry;   

DOI  :  10.1186/s12877-015-0067-3

 received in 2015-01-06, accepted in 2015-05-29,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundIn the 1990s, epidemiological studies estimated the prevalence of stroke caused by atrial fibrillation (AF) at about 15 %. Given the aging population, there is a rise in the number of AF patients. AF prevention guidelines based on clinical practice and the literature have been published and updated since 2001. Implementation seems to have an impact on the prescription of vitamin K antagonist (VKA). During the last 20 years, few population-based studies have focused on the prevalence of atrial arrhythmia (AA) in patients with stroke. The objective of the present prospective study, using data from 2008, was to evaluate the prevalence of AA (atrial fibrillation/flutter) in patients with stroke and the impact of implementing AF guidelines.MethodsThe prevalence of AA was studied in patients diagnosed with stroke from January 1 to December 31, 2008 in the population-based Stroke Registry of Brest, France (total population, 363,760 according to the 2008 census, with 295,553 aged 15 years or older). Guidelines implementation was assessed in terms of antithrombotic therapy (VKA, antiplatelet agent, none), and the CHADS2 (Congestive heart failure, Hypertension, Age > 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack).Results851 cases of stroke were identified. The prevalence of AA was 31.7 % (n = 264), and increased with age from < 20 % in patients aged 45 to 54 years to nearly 50 % in patients ≥ 85 years. In patients with AA, 231 strokes were ischemic, 28 hemorrhagic and 5 undetermined. At time of stroke, AA was known in 207 patients (78.4 %). 54 of the 152 patients with CHADS2 score ≥ 2 (35.5 %) were treated with VKA; this proportion decreased with age: 50 % between 50 and 74 years, 43.8 % between 75 and 84 years, and 25 % at 85 years and older.ConclusionThe prevalence of AA in the population-based Brest Stroke Registry in 2008 was higher than that reported by studies conducted 20 years ago. Despite publication of AF prevention guidelines, VKA prescription and use in elderly patients were significantly low.

【 授权许可】

Unknown   
© Jannou et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.